Solid Dosage
GEA provides proven solutions for manufacturing even the most challenging dosage forms of cardiovascular medication.
There are many types and combinations of medicines available to treat coronary heart disease (CHD), high blood pressure or heart failure, including anticoagulants, antiplatelet medications, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, calcium channel blockers, digoxin and diuretics.
Whatever the active ingredient, GEA provides proven solutions for even the most challenging dosage forms, such as MUPS tablets, effervescents and multi-layer dosage forms, as well as granules, pellets, modified/extended release formulations, powders designed for direct tableting or capsule filling and high-volume applications.
Still an important unit operation, coating is used to either add color, protect, mask the taste or create a modified release form in pharmaceutical production. GEA offers a range of standard, innovative, batch and continuous coater systems
Plus, as containment experts, the company offers the largest selection of solutions for contained processing based on a thorough containment risk analysis.
Providing increased yields, lower utility consumption and reduced waste, continuous manufacturing presents a new approach to high-volume oral dosage form production and meets the industry’s demands for faster product development, reduced costs, improved production economics and increased manufacturing flexibility.
Weergegeven 4 van 27

Door procesbewaking met behulp van online analysesystemen te combineren met vaste principes van procesengineering en geavanceerde procesmodelleringstechnieken, kunnen processen actief bestuurd worden om invoervariaties te compenseren.

Innovatieve CIP-concepten van GEA voldoen aan hoge normeringen. Onze experts garanderen productveiligheid in elke fase van het proces. Elke upgrade wordt aangepast aan individuele plaatselijke situaties en eisen van de klant, en leidt tot aanzienlijke besparingen.

Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.

The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
GEA’s past fiscal year was one of significant growth and further profitability gains. In particular, the technology group substantially increased order intake, with all divisions contributing here. GEA also made progress in all Mission 30 strategic growth areas. In addition, GEA met key interim targets under its climate plan ahead of schedule. Major milestones in fiscal year 2025 were admission to the DAX index, the award of one of the largest contracts in the company’s history, and streamlining of the corporate structure.
Dankzij een nieuwe SmartParc-productielocatie weten voedselverwerkende bedrijven in het Verenigd Koninkrijk hun bedrijfskosten en emissies terug te brengen. Met de GEA's verwarmings- en koeltechnologie in de kern laat dit op samenwerking gebaseerde productiemodel zien hoe innovatie de klimaatneutrale ambities van de industrie versnelt.
"Eieren brouwen is net als bier brouwen." Het is het soort vergelijking dat je doet glimlachen - en dan klikt het: iets ingewikkelds voelt plotseling eenvoudig. In deze persoonlijke film, die zich afspeelt in het agrarische hart van de VS, verkennen we precisiefermentatie en het echte werk dat nodig is om een idee om te zetten tot voedingsmiddelen.